Lir Life SciencesBBCMF 15 Cash Ratio is 11.74 as of Jan. 2026, which is 1298% above its 10-year median of 0.84. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,387 Biotechnology companies, Lir Life Sciences ranks better than 84.14% on this metric.
Lir Life Sciences has a Cash Ratio of 11.74. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lir Life Sciences's Cash Ratio or its related term are showing as below:
BBCMF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.84 Max: 26.84
Current: 11.81
During the past 2 years, Lir Life Sciences's highest Cash Ratio was 26.84. The lowest was 0.01. And the median was 0.84.
BBCMF's Cash Ratio is ranked better than 84.14% of 1387
companies
in the Biotechnology industry
Industry Median: 2.93
vs BBCMF: 11.81
Lir Life Sciences (OTCPK:BBCMF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lir Life Sciences Cash Ratio Related Terms
Lir Life Sciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lir Life Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a Cash Ratio of 11.74 as of Jan. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lir Life Sciences and its competitors. This is 1298% above median its historical median of 0.84. Over the past decade, Lir Life Sciences' Cash Ratio has ranged from 0.01 to 26.84. According to the industry distribution chart, Lir Life Sciences ranks #220 out of 1387 companies in the Biotechnology industry, placing it in the top 15.9%.
Is Lir Life Sciences' Cash Ratio too high?
Lir Life Sciences' current Cash Ratio of 11.74 is 1298% above median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 26.84. The Biotechnology industry median Cash Ratio is 2.93. Lir Life Sciences' value of 11.74 is 300.7% above this industry median. Based on the distribution chart, Lir Life Sciences ranks #220 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #220 out of 1387 companies for Cash Ratio. This places Lir Life Sciences in the top 16% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Lir Life Sciences' value of 11.74 is 300.7% above this benchmark. Historically, Lir Life Sciences' own Cash Ratio has ranged from 0.01 to 26.84 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 2.93, Lir Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,387 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Cash Ratio of 11.74 is 300.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Cash Ratio is 11.74, which is 1298% above median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Cash Ratio of 11.74. The current Cash Ratio is 11.74, which is 1298% above median its 10-year median of 0.84 and 300.7% above the Biotechnology industry median of 2.93. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Cash Ratio is 11.74 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 